Korea Pharma한국파마

Korea Pharma is back near break-even on a trailing basis after a loss-making 2025, while its share price has fallen about 40% over the past year.

Korea Pharma is a Korean prescription drug maker that also does contract manufacturing and exports to about 17 countries. For the twelve months to H1 2026 it reported revenue of ₩93.9B... more precisely ₩93.9B is shown as ₩93.9B, with an operating profit of ₩1.7B and a net loss of ₩0.9B. The stock closed at ₩8,110 on 2026-10-26, well below its 52-week high of ₩14,950.

What stands out

• Trailing revenue is about ₩93.9B and the operating margin is a thin 1.8%, against 7.5% in 2023 and 2024.
• Net income turned negative in both 2025 (about -₩2.6B) and the trailing period (about -₩0.9B), so return on equity is negative at -1.3%.
• Liabilities are 77.3% of equity, and borrowings (about ₩28.9B) are slightly above cash (about ₩28.5B).
• Trailing free cash flow is about ₩7.8B, which is positive even though accounting profit is negative.
• Recent filings include a buyback trust contract (2 Oct 2026) and several convertible bond acquisition and issuance disclosures in 2026; the data includes no news headlines.

What to watch

• The next quarterly or annual results, to see whether the operating margin can recover toward its earlier levels.
• Further filings on the convertible bonds and the buyback trust, which could affect the share count and balance sheet.
• The DCF fair value range in the data is ₩2,568 to ₩11,111 (base ₩5,626), well below the current price in the base case; this is a model output, not a forecast.